Increased prescribing trends of paediatric psychotropic medications
I C K Wong, M L Murray, D Camilleri-Novak and P Stephens
Arch. Dis. Child. 2004;89;1131-1132
doi:10.1136/adc.2004.050468

Updated information and services can be found at:
http://adc.bmj.com/cgi/content/full/89/12/1131

These include:

References
This article cites 4 articles, 1 of which can be accessed free at:
http://adc.bmj.com/cgi/content/full/89/12/1131#BIBL
8 online articles that cite this article can be accessed at:
http://adc.bmj.com/cgi/content/full/89/12/1131#otherarticles

Rapid responses
You can respond to this article at:
http://adc.bmj.com/cgi/eletter-submit/89/12/1131

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections
Drugs: psychiatry (441 articles)
Adolescent medicine (509 articles)
Children (1895 articles)

Correction
A correction has been published for this article. The contents of the correction have been appended to the original article in this reprint. The correction is also available online at:
http://adc.bmj.com/cgi/content/full/90/2/219-a

Notes
To order reprints of this article go to:
http://journals.bmj.com/cgi/reprlnform
To subscribe to Archives of Disease in Childhood go to:
http://journals.bmj.com/subscriptions/
Increased prescribing trends of paediatric psychotropic medications
I C K Wong, M L Murray, D Camilleri-Novak, P Stephens

Psychotropic medication use by children in the USA has increased. We used the IMS MIDAS Prescribing Insights to examine prescribing trends in nine countries between the years 2000 and 2002. Trends in seven countries rose significantly from year 2000 to 2002; the UK had the highest increase (68%).

Studies in the USA have shown that the use of psychotropic medications has increased considerably in recent years. We have previously reported a similar trend in the UK. However, there is little information on the prescribing trends in other countries; we do not know whether this is a global trend or a trend in English speaking countries. For the above reason, we used the IMS MIDAS Prescribing Insights to examine the prescribing trend of psychotropic medications in children in nine countries between the years 2000 and 2002.

METHODS
Children are defined as under 18 years old. The psychotropic medications investigated include antidepressants, stimulants, antipsychotics, benzodiazepines, and other anxiolytics.

IMS MIDAS Prescribing Insights contains the prescribing data from different countries. We obtained the paediatric psychotropic prescription data in the UK and three other European countries with the largest markets for these medications (France, Germany, and Spain), three South American countries with the largest markets for these medications (Argentina, Brazil, and Mexico) and North America (Canada and the USA).

RESULTS
Figure 1 shows that the number of psychotropic prescriptions for children has risen between the years 2000 and 2002 in all nine countries, and seven have shown a significant increase. The UK has the highest percentage increase (68%); the lowest was Germany (13%).

DISCUSSION
The results suggest that the increase in psychotropic prescribing in children is not only confined in the USA and UK but is also evident in other countries. The increase probably represents the improved recognition of paediatric psychopathology; there is also a concern that drugs are being used to replace non-drug treatments. However, there is insufficient research to confirm or refute the above suggestions. There are limitations to our data, especially as there is no information on the average prescription duration by drug or frequency, which may differ between years due to changes in prescribing practice. However, the observed increase in so many countries should raise concern, as little research has been conducted in children to study the effects of most psychotropic medications.

Table 1 Method of data collection in each country

<table>
<thead>
<tr>
<th>Countries by continent</th>
<th>No. of doctors involved in data collection</th>
<th>Stratification of sampling</th>
<th>Reporting time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Europe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>835</td>
<td>Region, age of doctor, community size, activity</td>
<td>7 consecutive days per quarter</td>
</tr>
<tr>
<td>Germany</td>
<td>2806</td>
<td>Region, specialty, community size</td>
<td>7 consecutive days per quarter</td>
</tr>
<tr>
<td>Spain</td>
<td>850</td>
<td>Region, year of doctor qualification</td>
<td>Daily throughout year (computerised GP records)</td>
</tr>
<tr>
<td>UK</td>
<td>500</td>
<td>Region, specialty, community size</td>
<td>7 consecutive days per quarter</td>
</tr>
<tr>
<td>South America</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Argentina</td>
<td>470</td>
<td>Region, specialty</td>
<td>7 consecutive days per quarter</td>
</tr>
<tr>
<td>Brazil</td>
<td>1155</td>
<td>Region, specialty</td>
<td>5 consecutive days</td>
</tr>
<tr>
<td>Mexico</td>
<td>1050</td>
<td>Region, specialty</td>
<td>Minimum of 4 consecutive days and maximum of 6 per quarter</td>
</tr>
<tr>
<td>North America</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td>1227 physicians report per month; 3678 physicians report per quarter</td>
<td>Two staged stratified cluster, randomly drawn</td>
<td>2 consecutive days per quarter</td>
</tr>
<tr>
<td>Canada</td>
<td>652</td>
<td>Region, specialty</td>
<td>2 consecutive days per quarter</td>
</tr>
</tbody>
</table>

IMS MIDAS Prescribing Insights is an audit drawn from a representative sample of medical practitioners in each country; table 1 summarises the details of data collection of each country. The prescribing data of sampled doctors were then adjusted according to the stratifications, and a projected national total of prescriptions data per year and 95.5% confidence intervals were calculated for each country. The within country differences of the data between years 2000 and 2002 were compared for significance.

www.archdischild.com
The recent recommendation by the Medicines and Healthcare products Regulatory Agency to withdraw selective serotonin inhibitors (SSRIs) from the treatment of paediatric depressive disorders* should serve as a lesson to all of us. The percentage of SSRI prescriptions from all antidepressants prescriptions issued to children and adolescents in the UK increased considerably between 1992 and 2001; it is probable that the rationale for drug choice is not based on the research evidence in children, but based on the evidence in adults. This highlights an important point which paediatric clinical pharmacologists and pharmacists always advocate—"children are not small adults".

Certainly we need more well designed clinical trials to investigate the safety and efficacy of psychotropic medications in children; it is also necessary to study how and why these medications are being prescribed, through the application of pharmacoepidemiology. We believe the use of psychotropic medications in children is a global public health issue, which should be studied in partnership with pharmaceutical companies, governments, and researchers to grow and expand the evidence base for their use in children. Children should not be deprived of safe and efficacious treatments.

ACKNOWLEDGEMENTS
IW's post is funded by the Department of Health Public Health Career Scientist Award. We thank IMS for providing the data.

REFERENCES
LETTERS

Expert witnesses: opinion and dogma are pitfalls in medical journalism as well as in reports

Professor David's leading article provides a welcome summary of the Code of Guidance for Expert Witnesses in Family Proceedings. All paediatricians who undertake this type of work should be familiar with the Code of Guidance and have due regard to it. However, Professor David also goes on to express some highly personal opinions which, while forcefully argued, are un referenced and not evidence based. The most obvious example in the article is Professor David's views on interviewing the parents or carers. He comments that a paediatrician who does not attempt to interview the parents risks being criticised for by-passing the usual routines and failing to consider all aspects of the case. He goes on to say that paediatricians should be reasoning that a doctor's prime role is to consider whether the child has suffered harm, not to attribute guilt.

(2) Given the long delay between the suspected abuse event and the involvement of the Expert Witness, there is a risk that perfectly innocent errors may creep into the history provided by the carers. There is a risk that the doctor or the court would be prejudiced against the parents in this situation.

(3) There is a further risk for the unwary in potentially becoming prejudiced against parents who are unable to provide a clear history; for example in cases where learning difficulties, unusual personalities, or strange affect. This is also to be guarded against, as it is essential for paediatricians to remain objective.

(4) The Expert Witness Guidance specifically forbids paediatricians to seek to resolve disputed issues of fact in their reports. There is a risk that in interviewing the family and generating new information the paediatrician may be drawn into this particular trap.

(5) In some cases there may be a risk of physical harm or intimidation of the Expert Witness. Often we are invited to meet with the family in their own home and without chaperones. This also leaves doctors vulnerable to false accusations concerning their behaviour in interviews. The carers may try to challenge or "cross-examine" the doctor at interview. Doctors need to consider carefully their own health and safety in these circumstances.

(6) The parents may misinterpret, misrepresent or take "false hope" from things that the paediatrician has said to them, or may press for a provisional opinion on the case, which of course should not be given.

(7) Not infrequently, parents or their advocates are suspicious about the paediatrician's motive in wanting to interview the family, even when the doctor is jointly instructed and acting in a completely neutral capacity. They may insist on the interview being recorded and transcribed, which adds delay and expense. If the interview is not recorded the carer may later deny something that they said to the paediatrician if it is unhelpful to their case.

(8) Given that the courts are experiencing extreme difficulty in recruiting Expert Witnesses, adding a further obligatory interview, regardless of its relevance, may deter paediatricians even further from taking on cases.

(9) The new Protocol for Family Law cases was introduced to avoid delay in proceedings and a requirement to interview carers in all cases would inevitably add delay.

(10) Parents often find interviews such as this very stressful. This is only justified if there is clear benefit.

(11) Finally, Professor David's views imply that avoidance of parental upset is a priority. It is to be expected that parents will be upset about the diagnosis of abuse, particularly if they are implicated. However, there is no evidence of which we are aware to suggest that the parents will be less upset, or less likely to complain, if the paediatrician meets with them.

Last year, the President of the Royal College of Paediatrics and Child Health drew attention to an "orchestrated campaign" against paediatricians involved in child protection. Certain well known campaigners, accused parents, and journalists often refer to the fact that a Paediatric Expert Witness had not met the family before coming to a diagnosis, in an attempt to discredit them. In this context, the idea that interviews with parents or carers should be conducted purely to appease them and reduce the likelihood of them complaining is highly controversial and there is no reason to believe that goal would be achieved. Where complaints are received, for example by an NHS Trust or the GMC, it is important that the doctor's performance is judged on the basis of currently accepted and "reasonable" medical practice, and that the opinions of those making these judgements are not influenced by skilfully argued, but personal and controversial views such as those expressed by Professor David.

In some cases, of course the Expert Witness will wish to meet with the carers before coming to a diagnosis. We would not argue that it is wrong to do so subject to the cautions mentioned above, but it should not be obligatory as suggested by Professor David. Ultimately the more objective evidence is contained in the medical records. A careful review of this basic information is often needed before deciding whether to take a further history from the parents. Whether or not the parents or carers have been interviewed should not be regarded as a measure of the quality of the report, and there are many occasions when reports based on paper reviews have been highly commended by courts. In each case paediatricians need to carefully weigh up the pros and cons of interviewing the carers and justify their actions.

Professor David quite correctly enters all paediatricians to consider both sides of the argument, acknowledge where opinions are controversial or open to challenge, and present material that does not support the Expert's opinion as well as that which does. He also points out that non-medical professionals such as lawyers and judges may over interpret medical theories. These cautions are well made, but we would suggest that they should also apply to controversial opinions expressed in the medical literature, particularly where they relate to Expert Witness work and could have serious unwanted consequences if they were to be taken without comment into medical or judicial dogma.